NCT01778413View on ClinicalTrials.gov

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 3, 2013

Primary Completion Date

November 14, 2014

Study Completion Date

July 21, 2015

Conditions
HIV
Interventions
DRUG

ATRIPLA

Trial Locations (1)

08036

Hospital Clinic i Provincial Barcelona, Barcelona

All Listed Sponsors
lead

Anna Cruceta

OTHER

NCT01778413 - Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine | Biotech Hunter | Biotech Hunter